Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company leverages advances in disease biology, including protein misfolding, lysosomal dysfunction, and immune and neuronal pathway disruption, to create product candidates that remove pathogenic proteins, replace deficient proteins, and restore normal cellular function. A core component of its strategy is the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier delivery technology designed to enhance central nervous system exposure for antibodies, enzymes, and siRNA therapeutics.

Alector generates revenue through collaboration agreements, licensing arrangements, and milestone payments from partnerships with pharmaceutical companies. The company has an active collaboration with GlaxoSmithKline (GSK) for the co-development and commercialization of nivisnebart and latozinemab, under which it received upfront payments and is eligible for additional milestone and royalty payments. Alector also earns revenue from prior collaborations, such as with Adimab, which supported the discovery and optimization of certain product candidates.

The company operates through the following segments:

• Nivisnebart Program: This segment focuses on the development of nivisnebart, an investigational monoclonal antibody designed to elevate progranulin levels by inhibiting the SORT1 receptor. Nivisnebart is being co-developed with GSK for the treatment of early Alzheimer’s disease and is currently in a Phase 2 clinical trial known as PROGRESS-AD. The program may also be evaluated for Parkinson’s disease based on genetic links between progranulin deficiency and neurodegeneration.

• AL137 Program: This segment develops AL137, a brain-penetrant anti-amyloid beta antibody paired with the Alector Brain Carrier (ABC) technology for the potential treatment of Alzheimer’s disease. AL137 is designed to remove amyloid plaques while minimizing amyloid-related imaging abnormalities and enabling subcutaneous delivery. The candidate is in preclinical development, with plans to submit an Investigational New Drug application in late 2026 or early 2027.

• AL050 Program: This segment advances AL050, a brain-penetrant glucocerebrosidase enzyme replacement therapy combined with ABC technology for Parkinson’s disease and Lewy body dementia in patients with GBA1 mutations. AL050 features an engineered enzyme with improved activity and stability, and preclinical studies show it increases enzyme activity and reduces toxic substrates in models of GBA deficiency. An IND application is targeted for 2027.

• ABC-Enabled siRNA Platform: This segment develops small interfering RNA therapeutics using the ABC platform for delivery across the blood-brain barrier. Lead programs include AL064, a tau-targeting siRNA for Alzheimer’s disease and other tauopathies, and earlier-stage candidates such as ADP062-ABC targeting alpha-synuclein for Parkinson’s disease and ADP065-ABC targeting NLRP3 for multiple neurodegenerative conditions. The platform aims to enable peripheral dosing and broad brain distribution.

Alector operates in the competitive biotechnology industry focused on neurodegenerative disease therapeutics, where it faces competition from large pharmaceutical companies such as Biogen, Eli Lilly, Merck, Roche, and Eisai, which are also developing treatments for Alzheimer’s and Parkinson’s disease. The company’s competitive advantages include its proprietary ABC platform for brain delivery, its genetically validated targets, and its integrated capabilities in protein engineering, antibody discovery, and biomarker development.

Alector’s customer base consists primarily of pharmaceutical partners and clinical trial sites involved in the development and testing of its product candidates. The company collaborates with GSK on the nivisnebart and latozinemab programs and works with contract development and manufacturing organizations to support preclinical and clinical production. Its therapies are intended for patients suffering from neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia.